Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions-Reference-Cited by-同舟云学术

Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions

Published:2014-07-07 Issue:7 Volume:9 Page:e101576
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wang Joshua W.,Jagu Subhashini,Wang Chenguang,Kitchener Henry C.,Daayana Sai,Stern Peter L.,Pang Susana,Day Patricia M.,Huh Warner K.,Roden Richard B. S.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference56 articles.

1. Virus infection and human cancer: an overview;JT Schiller;Recent Results Cancer Res,2014

2. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic;R Kirnbauer;Proc Natl Acad Sci U S A,1992

3. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product;YL Lin;J Virol,1993

4. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection;F Breitburd;J Virol,1995

5. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine;CD Harro;J Natl Cancer Inst,2001

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model;Vaccines;2024-06-20

2. Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2;Frontiers in Immunology;2023-11-08

3. Pseudotyped Virus for Papillomavirus;Advances in Experimental Medicine and Biology;2023

4. Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development;Frontiers in Immunology;2022-10-03

5. Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity;Journal for ImmunoTherapy of Cancer;2022-04